April 16 (Reuters) - Abbott Laboratories ABT.N beat Wall Street estimates for first-quarter profit on Wednesday, buoyed by strong demand for diabetes care and other medical devices.
The company also maintained its full-year profit forecast of $5.05 to $5.25 per share in the face of an escalating global trade war.
Abbott is likely to face a hit from the heavy duties imposed on other countries given its broad manufacturing footprint across the world, according to analysts.
On an adjusted basis, the company's quarterly profit of $1.09 per share beat analysts' average expectations of $1.07 per share, according to estimates compiled by LSEG.
(Reporting by Christy Santhosh and Puyaan Singh in Bengaluru; Editing by Leroy Leo)
((Christy.Santhosh@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。